Journal
BIOCONJUGATE CHEMISTRY
Volume 29, Issue 11, Pages 3776-3782Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.bioconjchem.8b00640
Keywords
-
Categories
Funding
- Memorial Sloan Kettering Cancer Center's Animal Imaging Core Facility and Molecular Imaging Probes Core Facility
- National Institutes of Health [P30 CA008748, R01 HL125703, R01 CA204441, K99 CA218875, R01 CA204441-03S1]
- Memorial Sloan Kettering Cancer Center's Nuclear Magnetic Resonance Analytical Core Facility
Ask authors/readers for more resources
The preclinical potential of many diagnostic and therapeutic small molecules is limited by their rapid washout kinetics and consequently modest pharmacological performances. In several cases, these could be improved by loading the small molecules into nanoparticulates, improving blood half-life, in vivo uptake and overall pharmacodynamics. In this study, we report a nanoemulsion (NE) encapsulated form of PARPi-FL. As a proof of concept, we used PARPi-FL, which is a fluorescently labeled sensor for olaparib, a FDA-approved small molecule inhibitor of the nuclear enzyme poly(ADP-ribose)polymerase 1 (PARP1). Encapsulated PARPi-FL showed increased blood half-life, and delineated subcutaneous xenografts of small cell lung cancer (SCLC), a fast-progressing disease where efficient treatment options remain an unmet clinical need. Our study demonstrates an effective method for expanding the circulation time of a fluorescent PARP inhibitor, highlighting the pharmacokinetic benefits of nanoemulsions as nanocarriers and confirming the value of PARPi-FL as an imaging agent targeting PARP1 in small cell lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available